Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Retatrutide is an investigational medication not approved by the FDA as of April 2026
FDA-approved semaglutide brands and indications Brand Ozempic (injectable) Approval date December 2017 Indication Type 2 diabetes glycemic control Brand Ozempic (injectable) Approval date January 2020 Indication Cardiovascular risk reduction in T2D Brand Rybelsus (oral tablet) Approval date September 2019 Indication Type 2 diabetes (first oral GLP-1) Brand Wegovy (injectable) Approval date June 2021 Indication Chronic weight management (BMI 30 or 27 with comorbidity) Brand Wegovy (injectable) Approval date March 2024 Indication Cardiovascular risk reduction in adults with obesity and CVD Brand Wegovy (injectable) Approval date August 2025 Indication Non-cirrhotic MASH with F2-F3 fibrosis (ESSENCE) Brand Wegovy oral 25 mg pill Approval date December 2025 Indication Chronic weight management (OASIS 4 basis) Brand Ozempic (injectable) Approval date February 2026 Indication CKD progression in T2D (FLOW basis) Research-grade lyophilized semaglutide from supplier sources is not an FDA-approved drug product and is for research use only
These metabolic pathways are essential for the production of adenosine triphosphate (ATP), via ATP synthase, the primary energy source of cells (14)
How GLP-1 Medications Work GLP-1 medications work by mimicking the action of the natural hormone GLP-1, which is produced in the small intestine
Noroviruses, the most common cause of these symptoms, affect an estimated 19 to 21 million people in the U.S
and G.B.H., P30AG050886 to D.B.A
